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In healthcare facilities, transmission of ID-MRSA from
a HCW to a patient has been postulated. In an earlier
report, a HCWwas colonized with MRSA after treatment with
cephalexin. Exposure to the antibiotic was the purported
inducer of phenotypic resistance. Until recently, there have
been no prior epidemiological reports of ID-MRSA in the non-
healthcare setting. A prospective epidemiologic surveillance
study identiﬁed ID MRSA in a cohort of healthy university
students. The potential impact of ID-MRSA colonization on
CA-MRSA colonization and subsequent development of skin
and soft tissue infections or invasive disease is not known.
As in the hospital setting, ID-MRSA colonization may serve
as a reservoir, thereby promoting cross-transmission within
a household, dormitory, athletic team or social unit. Colo-
nized individuals may theoretically cross transmit ID-MRSA
isolates to close contacts. Additionally, ID-MRSA colonization
or transmission may result in MRSA phenotypic conversion if
the appropriate selective antibiotic pressure is applied. Fur-
thermore, individuals persistently colonized with ID-MRSA
may play an important role in households with high rates
of CA-MRSA infections. Further studies are needed to better
deﬁne both mechanisms of resistance and the epidemiologic
signiﬁcance of ID-MRSA.
doi:10.1016/j.ijid.2010.02.1503
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The Role of PVL in Severe Disease - What is the Evidence?
K. Christiansen
Royal Perth Hospital, Perth, Australia
ST8-MRSA-IV (USA300), ST80-MRSA-IV (European clone),
ST59-MRSA-IV (Taiwan clone) and in Australia ST93-MRSA-
IV (Queensland clone) and ST30-MRSA-IV (Oceania clone)
are all PVL positive. Data from Australia where CA-MRSA
has been described since the late 1980’s show that disease
severity and demographics vary widely between PVL positive
and negative clones.
Demonstrating the actual role of PVL in disease has been
controversial. Mouse and rat animal models using PVL pos-
itive and negative clones or PVL deleted mutants have
provided some support for a role in muscle damage, skin
abscess and lung necrosis but there are studies that fail
to show any association of PVL with pathogenesis of CA-
MRSA disease. In contrast rabbit models have demonstrated
a role in lung necrosis, dermatonecrosis and osteomyelitis
- a reﬂection of the greater sensitivity of rabbit polymor-
phonuclear (PMN) leucocytes to PVL than murine PMNs.
As with most biological systems one single factor is rarely
the explanation for a complex disease. Other virulence
factors have been described for CA-MRSA including core
genomic factors such as alpha haemolysin, secreted pro-
teases, phenol-soluble modulins (PSMs), increased expres-
sion of the accessory gene regulator (agr) and especially for
USA300 the possession of the arginine catabolic mobile ele-
ment (ACME) that has a role in pH homeostasis, ﬁtness and
possibly transmission. More recently PSMs that are associ-
ated with the SCCmec have been described.
Conclusion: PVL is not necessarily a driver of the CA-
MRSA epidemics being seen worldwide but is more likely a
determinant of signiﬁcant skin and soft tissue infection with
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bscess formation as well as more severe disease such as
ecrotising pneumonia, necrotising fasciitis and osteomyeli-
is.
oi:10.1016/j.ijid.2010.02.1504
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RSA Control Programs in the UK: Impact on Quality of
are, Nosocomial Infection, and Public Perception
. Gould
Royal Inﬁrmary, Aberdeen, Saudi Arabia
Driven largely by public and hence political pressure,
he NHS has made good progress in reducing MRSA bacter-
emia. By the end of June 2009, they had fallen to 26%
f 2003-04 levels in England and Wales. Little data how-
ver, is available on background MRSA colonisation rates or
ther types of infection although HAI audits suggest MRSA
s still the dominant cause of postoperative wound infec-
ion. Signiﬁant resource is now being invested in universal
dmission screening and early signs are that this is being
uccessful with signigicant reduction in colonization rate
t admission, overall burden on isolations rooms, clincially
iagnosed infections and laboratory clinical isolates. The
ittle evidence available suggests that the public is happy
ith screening programmes. Nevertheless, signiﬁcant con-
erns remain at public health level about the use of these
esources for MRSA screening and at an ethical level about
he enforced isolations of patients with possible detrimental
ffects on quality of care.
oi:10.1016/j.ijid.2010.02.1505
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RSA epidemiology and Control in Developing Countries
. Rosenthal
International Nosocomial Infection Control Consortium
INICC), Buenos Aires, Argentina
International infection control consortium (INICC)
eported data from January 2003 through December 2008
n 173 ICUs in Latin America, Asia, Africa, and Europe.
uring the 6-year study, using CDC NNIS/NHSN deﬁnitions
or device-associated healthcare-associated infection, we
ollected prospective data from 155,358 patients hospital-
zed in the consortium’s hospital ICUs for an aggregate of
23,624 days.
Although device utilization in the developing countries’
CUs was remarkably similar to that reported from U.S.
CUs in the CDC’s NHSN, rates of device-associated noso-
omial infection were markedly higher in the ICUs of the
NICC hospitals: the pooled rate of CVC-associated BSI in
he INICC ICUs, 7.6 per 1000 CVC days, is nearly three-
old higher than the 2.0 per 1000 CVC-days reported from
omparable U.S. ICUs, and the overall rate of ventilator-
ssociated pneumonia (VAP) was also far higher, 13.6 vs
.3 per 1000 ventilator-days, as was the rate of catheter-
ssociated urinary tract infection (CAUTI), 6.3 vs. 3.3 per
000 catheter-days.
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Most strikingly, the frequencies of resistance of Staphy-
ococcus aureus isolates to methicillin—–MRSA (84.1% vs
6.8%), Klebsiella pneumoniae to ceftazidime or cef-
riaxone (76.1% vs 27.1%), Acinetobacter baumannii to
mipenem (46.3% vs 29.2%), and Pseudomonas aeruginosa
o piperacilline (78.0% vs 20.2%) were also far higher in
he consortium’s ICUs, and the crude unadjusted excess
ortalities of device-related infections ranged from 23.6%
CVC-associated BSI) to 29.3% (VAP).
oi:10.1016/j.ijid.2010.02.1506
easonal ﬂu vaccines: Current status and future
irections (Invited Presentation)
1.001
nﬂuenza vaccination: Where do we stand?
.E. Fiore
National Center for Infectious Diseases, CDC, Atlanta, GA,
SA
In the United States, inﬂuenza causes an average of
6,000 deaths and 226,000 hospitalizations yearly. Rates of
nfection are highest among children. Rates of serious ill-
ess and death are highest among persons aged ‘‘65 years,
hildren aged <2 years, and persons of any age with medical
onditions that place them at higher risk for complications
rom inﬂuenza.
Annual inﬂuenza vaccination is the most effective
ethod for preventing inﬂuenza virus infection and its
omplications. Inﬂuenza viruses undergo frequent antigenic
hange (antigenic drift); patients need an annual vacci-
ation against the inﬂuenza viruses that are predicted on
he basis of viral surveillance data. Trivalent inactivated
nﬂuenza vaccine (TIV) can be used for any person aged
‘6 months, including those with high-risk conditions. Live,
ttenuated inﬂuenza vaccine (LAIV) may be used for healthy,
onpregnant persons aged 2—49 years.
The 2009 novel inﬂuenza A (H1N1) pandemic required
separate monovalent vaccine to be rapidly developed,
ith different vaccination recommendations from those for
easonal vaccines. The initially limited supply of vaccine
equired that early vaccination efforts target children and
oung adults, adults <65 years old with chronic medical
onditions, pregnant women, and healthcare personnel. By
anuary 2010, monovalent vaccine supply had increased suf-
ciently to allow all persons who wanted vaccination to
eceive it.
Vaccination coverage has remained low in most groups
or a variety of reasons, including the need for annual revac-
ination, the complexity of vaccination recommendations,
nd a lack of knowledge among patients and healthcare
roviders. In recent years, simpler age-based recommen-
ations have been added for persons 50-64 years old, and
hildren ages 6 months through 18 years, and in 2009, >85%
f the US population had an indication for annual vacci-
ation. As more manufacturers have entered the market,
easonal vaccine supply has met demand. A universal vac-
ine recommendation for all persons aged 6 months or older
s feasible and has been proposed as a way to increase vac-
ine coverage in all age groups.
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Current inﬂuenza vaccines are safe in all age and risk
roups and quite effective in healthy children and younger
dults. Lower effectiveness among seniors and persons
ith chronic medical conditions, and lower immunogenicity
requiring 2 doses) among previously unvaccinated infants
nd children highlight unmet challenges. More effective vac-
ines are needed that can be more rapidly produced and can
vercome challenges such as immunosenescence, annual
evaccination, and lower protection against drifted viruses.
deally, better vaccines would stimulate longer-lasting cross-
eactive immunity against multiple strains.
Vaccines must be effective in protecting the very young,
he chronically ill, and the elderly, who bear the largest
urden of inﬂuenza illness. Also needed is a better under-
tanding of how to motivate people to seek annual inﬂuenza
accination.
oi:10.1016/j.ijid.2010.02.1507
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vercoming limitations of seasonal vaccines
.S. Monto
University of Michigan School of Public Health, Ann Arbor,
I, USA
Among the limitations of seasonal inﬂuenza vaccines are
imited breadth of immunity, short duration of protection,
ower protection in older individuals and immunocompro-
ised patients, problems with needle inoculation such as
eedle phobia and medical waste disposal, and dependence
n the egg supply. Because antigenic drift (poor antigenic
atch between the vaccine and circulating strains) is asso-
iated with a fall in efﬁcacy, there is a need for vaccines
hat will induce an immune response to both identical and
elated strains. In an effort to produce broadened immunity,
ew adjuvanted vaccines with different oil components have
een formulated, and the concept of a universal inﬂuenza
accine continues to be explored. It is not clear whether
roducing a higher titer postvaccination will result in longer
uration of protection, as that requires speciﬁc evaluation
nvolving major practical difﬁculties. Improved technology
or inﬂuenza vaccines may result in vaccines intended for
peciﬁc population segments, such as younger children and
he elderly. A quadrivalent vaccine may be developed con-
aining the two A subtypes and the two B lineages, which
ould be most useful in children. To combat the issue of
mmunosenescence, a high-dose vaccine has recently been
pproved for use in older patients. Some studies suggest that
nvaccinated older individuals may be more ill but because
f their disability, underutilize the healthcare system; in
ontrast, vaccinated older individuals may be healthier
ecause they are in care, indicating bias in analyses. It may
e possible that these new vaccines will produce protec-
ion in the immunocompromised, but this will need to be
valuated speciﬁcally. To address problems associated with
eedle inoculation, new delivery systems and alternative
outes to intramuscular administration have been devel-
ped, such as a nasal vaccine approved in the United States
n 2007 and an intradermal vaccine approved recently in
urope. Cell culture production of inﬂuenza vaccines may
mprove vaccine efﬁcacy and would reduce the system’s
